These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30999967)

  • 1. Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
    Chen N; Dowd S; Gatton ML; Auliff A; Edstein MD; Cheng Q
    Malar J; 2019 Apr; 18(1):140. PubMed ID: 30999967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 2D6 profiles and anti-relapse efficacy of tafenoquine against
    Dowd S; Chen N; Gatton ML; Edstein MD; Cheng Q
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0101423. PubMed ID: 37971260
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
    Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
    JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
    Martin Ramírez A; Lombardia González C; Soler Maniega T; Gutierrez Liarte Á; Domingo García D; Lanza Suárez M; Bernal Fernández MJ; Rubio JM
    Malar J; 2020 Jul; 19(1):259. PubMed ID: 32680522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
    He X; Pan M; Zeng W; Zou C; Pi L; Qin Y; Zhao L; Qin P; Lu Y; Baird JK; Huang Y; Cui L; Yang Z
    BMC Infect Dis; 2019 Aug; 19(1):704. PubMed ID: 31399061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses.
    Puça MCSB; Rodrigues DF; Salazar YEAR; Louzada J; Fontes CJF; Daher A; Pereira DB; Fernandes Vieira JL; Carvalho LH; Alves de Brito CF; Gil JP; Nobrega de Sousa T
    J Antimicrob Chemother; 2024 Aug; 79(8):1985-1989. PubMed ID: 38870082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
    Baird JK; Battle KE; Howes RE
    Malar J; 2018 Jan; 17(1):42. PubMed ID: 29357870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.
    Silvino ACR; Kano FS; Costa MA; Fontes CJF; Soares IS; de Brito CFA; Carvalho LH; Sousa TN
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122891
    [No Abstract]   [Full Text] [Related]  

  • 9. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
    Brasil LW; Rodrigues-Soares F; Santoro AB; Almeida ACG; Kühn A; Ramasawmy R; Lacerda MVG; Monteiro WM; Suarez-Kurtz G
    Malar J; 2018 Feb; 17(1):57. PubMed ID: 29390987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function.
    Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Oh HS; Kim YC; Yeom JS; Han JH; Kim MJ
    Korean J Parasitol; 2022 Feb; 60(1):39-43. PubMed ID: 35247953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea.
    Ingram RJ; Crenna-Darusallam C; Soebianto S; Noviyanti R; Baird JK
    Malar J; 2014 Dec; 13():488. PubMed ID: 25495607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
    St Jean PL; Xue Z; Carter N; Koh GC; Duparc S; Taylor M; Beaumont C; Llanos-Cuentas A; Rueangweerayut R; Krudsood S; Green JA; Rubio JP
    Malar J; 2016 Feb; 15():97. PubMed ID: 26888075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients.
    Choi S; Choi H; Park SY; Kwak YG; Song JE; Shin SY; Baek JH; Shin HI; Cho SH; Lee SE; Kwon JR; Park S; Kim M; Oh HS; Kim YC; Kim MJ; Yeom JS
    Malar J; 2022 Oct; 21(1):289. PubMed ID: 36217154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.
    Chamchoy K; Sudsumrit S; Thita T; Krudsood S; Patrapuvich R; Boonyuen U
    PLoS Negl Trop Dis; 2022 Dec; 16(12):e0010986. PubMed ID: 36508454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of CYP2D6 Genotypes and Predicted Phenotypes in a Cohort of Cambodians at High Risk for Infections with
    Spring MD; Lon C; Sok S; Sea D; Wojnarski M; Chann S; Kuntawunginn W; Kheang Heng T; Nou S; Arsanok M; Sriwichai S; Vanachayangkul P; Lin JT; Manning JE; Jongsakul K; Pichyangkul S; Satharath P; Smith PL; Dysoley L; Saunders DL; Waters NC
    Am J Trop Med Hyg; 2020 Aug; 103(2):756-759. PubMed ID: 32394887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of CYP2D6 gene polymorphisms in the full-length coding region with higher recurrence rate of vivax malaria in Yunnan Province, China.
    Huang H; Dong Y; Xu Y; Deng Y; Zhang C; Liu S; Chen M; Liu Y
    Malar J; 2021 Mar; 20(1):160. PubMed ID: 33743705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine.
    Daher A; Aljayyoussi G; Pereira D; Lacerda MVG; Alexandre MAA; Nascimento CT; Alves JC; da Fonseca LB; da Silva DMD; Pinto DP; Rodrigues DF; Silvino ACR; de Sousa TN; de Brito CFA; Ter Kuile FO; Lalloo DG
    Malar J; 2019 Sep; 18(1):325. PubMed ID: 31547827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses.
    Silvino AC; Costa GL; Araújo FC; Ascher DB; Pires DE; Fontes CJ; Carvalho LH; Brito CF; Sousa TN
    PLoS One; 2016; 11(7):e0160172. PubMed ID: 27467145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.
    Spring MD; Sousa JC; Li Q; Darko CA; Morrison MN; Marcsisin SR; Mills KT; Potter BM; Paolino KM; Twomey PS; Moon JE; Tosh DM; Cicatelli SB; Froude JW; Pybus BS; Oliver TG; McCarthy WF; Waters NC; Smith PL; Reichard GA; Bennett JW
    J Infect Dis; 2019 Oct; 220(11):1761-1770. PubMed ID: 31549155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP2D6 Genetic Variation on Radical Cure of Plasmodium vivax Malaria.
    Suarez-Kurtz G
    Clin Pharmacol Ther; 2021 Sep; 110(3):595-598. PubMed ID: 34042179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.